U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H22N6O2
Molecular Weight 414.4598
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOMELOTINIB

SMILES

O=C(NCC#N)C1=CC=C(C=C1)C2=NC(NC3=CC=C(C=C3)N4CCOCC4)=NC=C2

InChI

InChIKey=ZVHNDZWQTBEVRY-UHFFFAOYSA-N
InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19295546 | https://www.ncbi.nlm.nih.gov/pubmed/23459451

Momelotinib (CYT387) is an ATP-competitive small molecule that potently inhibits JAK1/JAK2 kinases. Momelotinib is developing by Gilead Sciences for the oral treatment of pancreatic and non-small cell lung cancers, and myeloproliferative disorders (including myelofibrosis, essential thrombocythaemia and polycythaemia vera).

CNS Activity

Curator's Comment: Momelotinib (CYT387) is brain penetrant in mice. No human data available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
11.0 nM [IC50]
18.0 nM [IC50]
Conditions
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 5.8048 uM]
Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
2009 Aug
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
2009 Oct 15
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
2011 Dec
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
2014 May 6
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
2017 Feb
Patents

Sample Use Guides

150-300 mg/day. Maximum tolerated dose of momelotinib was found to be 300 mg/day in the phase I portion of a phase I/II study (NCT00935987) in patients with myelofibrosis. At the higher dose level of 400 mg/day, two of six patients experienced dose-limiting toxicities.
Route of Administration: Oral
0.5 and 1.5 uM CYT387 caused growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines, while nonhematopoietic cell lines were unaffected.
Name Type Language
MOMELOTINIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
MOMELOTINIB [USAN]
Common Name English
Momelotinib [WHO-DD]
Common Name English
CYT387
Code English
CYT-0387
Code English
CYT-387
Code English
CYT-11387
Common Name English
momelotinib [INN]
Common Name English
N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE
Systematic Name English
GS-0387
Code English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
FDA ORPHAN DRUG 311610
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
Code System Code Type Description
DRUG BANK
DB11763
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
NCI_THESAURUS
C88311
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
USAN
XX-160
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
INN
9480
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
FDA UNII
6O01GMS00P
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
EPA CompTox
DTXSID801026049
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
SMS_ID
100000163080
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
PUBCHEM
25062766
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
WIKIPEDIA
CYT387
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
ChEMBL
CHEMBL1078178
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
CHEBI
91407
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
CAS
1056634-68-4
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY
EVMPD
SUB177206
Created by admin on Sat Dec 16 17:21:48 UTC 2023 , Edited by admin on Sat Dec 16 17:21:48 UTC 2023
PRIMARY